Literature DB >> 12595050

A636P is associated with early-onset colon cancer in Ashkenazi Jews.

José G Guillem1, Beth S Rapaport, Tomas Kirchhoff, Prema Kolachana, Khedoudja Nafa, Emily Glogowski, Rob Finch, Helen Huang, William D Foulkes, Arnold Markowitz, Nathan A Ellis, Kenneth Offit.   

Abstract

BACKGROUND: Hereditary predisposition to colorectal cancer most often manifests itself as familial adenomatous polyposis from mutations of APC, or hereditary nonpolyposis colorectal cancer, resulting from mutations of MSH2, MLH1, MSH6, or other genes. Previously, we described a rare founder mutation MSH2*1906C > G in Ashkenazi Jews that was found in 8 of 1,345 individuals (0.6%) of Ashkenazi descent with colorectal cancer. This study seeks to characterize the proportion of individuals of Ashkenazi heritage with very early-onset colon cancer (diagnosed at age 40 or younger) that could be attributed to MSH2*1906C>G. STUDY
DESIGN: We analyzed the carrier frequency of MSH2*1906C>G in paraffin samples from 31 Jewish patients age 40 or less, diagnosed with colorectal cancer at Memorial Sloan-Kettering and lymphocyte-derived DNA from 10 patients. We did not select for family history. Genotyping for MSH2*1906C>G was performed by polymerase chain reaction and restriction enzyme digestion methods.
RESULTS: We detected the MSH2*1906G>C mutation in 3 of the 41 samples (7.14%) of patients who had colorectal cancer diagnosed at age 40 or younger. This incidence is significantly greater than the 8 in 1,345 (0.6%) we observed for cases of colorectal cancer in Ashkenazi Jews not selected for age (p = 0.004).
CONCLUSION: Although very rare in the population, MSH2*1906G>C is found at an increased frequency in young Jewish patients with colorectal cancer. These results suggest that testing for the MSH2*1906G>C mutation should be included in the evaluation of Ashkenazi Jewish individuals diagnosed with early-onset colon cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595050     DOI: 10.1016/S1072-7515(02)01808-2

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  12 in total

1.  Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.

Authors:  Sarah M Nielsen; Lenika M De Simone; Olufunmilayo I Olopade
Journal:  J Genet Couns       Date:  2018-06-26       Impact factor: 2.537

2.  The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.

Authors:  Yael Laitman; Liron Herskovitz; Talia Golan; Bella Kaufman; Shani Shimon Paluch; Eitan Friedman
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

3.  High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.

Authors:  Bhramar Mukherjee; Gad Rennert; Jaeil Ahn; Sara Dishon; Flavio Lejbkowicz; Hedy S Rennert; Stacey Shiovitz; Victor Moreno; Stephen B Gruber
Journal:  Gastroenterology       Date:  2011-03-16       Impact factor: 22.682

4.  Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas.

Authors:  Nicola S Fearnhead; Jennifer L Wilding; Bruce Winney; Susan Tonks; Sylvia Bartlett; David C Bicknell; Ian P M Tomlinson; Neil J McC Mortensen; Walter F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-01       Impact factor: 11.205

5.  MSH2 Loss in Primary Prostate Cancer.

Authors:  Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-08-08       Impact factor: 12.531

Review 6.  Genetic factors and colorectal cancer in Ashkenazi Jews.

Authors:  Gershon Y Locker; Henry T Lynch
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 7.  Cancer in Jews: introduction and overview.

Authors:  Henry T Lynch; Wendy S Rubinstein; Gershon Y Locker
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 8.  A636P testing in Ashkenazi Jews.

Authors:  Jose G Guillem; Harvey G Moore; Crystal Palmer; Emily Glogowski; Rob Finch; Khedoudja Nafa; Arnold J Markowitz; Kenneth Offit; Nathan A Ellis
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

9.  Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes.

Authors:  Frank Grünhage; Matthias Jungck; Christoph Lamberti; Christine Berg; Ursula Becker; Hildegard Schulte-Witte; Dominik Plassmann; Nils Rahner; Stefan Aretz; Nicolaus Friedrichs; Reinhard Buettner; Tilman Sauerbruch; Frank Lammert
Journal:  Int J Colorectal Dis       Date:  2007-10-25       Impact factor: 2.571

10.  Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management.

Authors:  Jose G Guillem; Emily Glogowski; Harvey G Moore; Khedoudja Nafa; Arnold J Markowitz; Jinru Shia; Kenneth Offit; Nathan A Ellis
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.